Plazomicin Sulfate
FDA-approved product (solution, intravenous), marketed as Zemdri.
- Registered studies
- 0
- Lab records
- 11
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Bacterial disease
- Pyelonephritis
- Urinary tract infection
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other aminoglycosides
- Anti-infective classification
- Classified as an existing antimicrobial.WHO ATC J01GB14
Repurposing investigation
Plazomicin Sulfate is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.
AI-predicted activity
AI prediction · nothing measured- MRSA58.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli57.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae90.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- M. tuberculosis47.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
No evidence found
The registry was searched and no registered study names this medicine.
Experimental
- K. pneumoniae: measured active in 11 of 11 lab records
Show the 11 laboratory records, with sources
Loading records…
“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Plazomicin Sulfate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Raltegravir PotassiumExisting use: HIV infection, HIV-1 infection, Immunodeficiency disease59.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- SelpercatinibExisting use: Cancer, Medullary thyroid gland carcinoma, Neoplasm and 4 more59.0% AI-predicted activityagainst M. tuberculosis42 registered studies
- SulindacExisting use: Osteoarthritis, Rheumatic disease, Rheumatoid arthritis and 1 more59.0% AI-predicted activityagainst M. tuberculosis40 registered studies
- SumatriptanExisting use: Migraine disorder59.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- SuvorexantExisting use: Insomnia59.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- TravoprostExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma59.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Sunitinib MalateExisting use: Cancer, Clear cell renal carcinoma, Gastrointestinal stromal tumor and 6 more59.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Delavirdine MesylateExisting use: Viral disease58.9% AI-predicted activityagainst M. tuberculosis27 registered studies
- Desmopressin AcetateExisting use: Central diabetes insipidus, Diabetes insipidus, Enuresis and 5 more58.9% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Terlipressin AcetateExisting use: Hepatorenal syndrome, Kidney failure, Renal insufficiency58.9% AI-predicted activityagainst M. tuberculosis7 registered studies
- Amlodipine MaleateExisting use: Angina pectoris, Cardiovascular disease, Congestive heart failure and 11 more58.8% AI-predicted activityagainst M. tuberculosis2 registered studies
- Indocyanine GreenExisting use: Other diagnostic agents58.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
No evidence found: the registry was searched and no registered study names this medicine.